Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus
Rupkatha Mukhopadhyay, Sujayita Roy, Rajkumar Venkatadri, Yu-Pin Su, Wenjuan Ye, Elena Barnaeva, Lesley Mathews Griner, Noel Southall, Xin Hu, Amy Q Wang, Xin Xu, Andrés E Dulcey, Juan J Marugan, Marc Ferrer, Ravit Arav-Boger, Rupkatha Mukhopadhyay, Sujayita Roy, Rajkumar Venkatadri, Yu-Pin Su, Wenjuan Ye, Elena Barnaeva, Lesley Mathews Griner, Noel Southall, Xin Hu, Amy Q Wang, Xin Xu, Andrés E Dulcey, Juan J Marugan, Marc Ferrer, Ravit Arav-Boger
Abstract
Infection with human cytomegalovirus (HCMV) is a threat for pregnant women and immunocompromised hosts. Although limited drugs are available, development of new agents against HCMV is desired. Through screening of the LOPAC library, we identified emetine as HCMV inhibitor. Additional studies confirmed its anti-HCMV activities in human foreskin fibroblasts: EC50-40±1.72 nM, CC50-8±0.56 μM, and selectivity index of 200. HCMV inhibition occurred after virus entry, but before DNA replication, and resulted in decreased expression of viral proteins. Synergistic virus inhibition was achieved when emetine was combined with ganciclovir. In a mouse CMV (MCMV) model, emetine was well-tolerated, displayed long half-life, preferential distribution to tissues over plasma, and effectively suppressed MCMV. Since the in vitro anti-HCMV activity of emetine decreased significantly in low-density cells, a mechanism involving cell cycle regulation was suspected. HCMV inhibition by emetine depended on ribosomal processing S14 (RPS14) binding to MDM2, leading to disruption of HCMV-induced MDM2-p53 and MDM2-IE2 interactions. Irrespective of cell density, emetine induced RPS14 translocation into the nucleus during infection. In infected high-density cells, MDM2 was available for interaction with RPS14, resulting in disruption of MDM2-p53 interaction. However, in low-density cells the pre-existing interaction of MDM2-p53 could not be disrupted, and RPS14 could not interact with MDM2. In high-density cells the interaction of MDM2-RPS14 resulted in ubiquitination and degradation of RPS14, which was not observed in low-density cells. In infected-only or in non-infected emetine-treated cells, RPS14 failed to translocate into the nucleus, hence could not interact with MDM2, and was not ubiquitinated. HCMV replicated similarly in RPS14 knockdown or control cells, but emetine did not inhibit virus replication in the former cell line. The interaction of MDM2-p53 was maintained in infected RPS14 knockdown cells despite emetine treatment, confirming a unique mechanism by which emetine exploits RPS14 to disrupt MDM2-p53 interaction. Summarized, emetine may represent a promising candidate for HCMV therapy alone or in combination with ganciclovir through a novel host-dependent mechanism.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
- Griffiths PD, Clark DA, Emery VC (2000) Betaherpesviruses in transplant recipients. J Antimicrob Chemother 45 Suppl T3: 29–34.
- Kovacs A, Schluchter M, Easley K, Demmler G, Shearer W et al. (1999) Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 341: 77–84.
- Demmler GJ (1991) Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 13: 315–329.
- Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK (2013) The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev 26: 86–102. 26/1/86 [pii];10.1128/CMR.00062-12
- Prichard MN, Kern ER (2011) The search for new therapies for human cytomegalovirus infections. Virus Res 157: 212–221. 10.1016/j.virusres.2010.11.004
- Schreiber A, Harter G, Schubert A, Bunjes D, Mertens T et al. (2009) Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother 10: 191–209. 10.1517/14656560802678138
- Steininger C (2007) Novel therapies for cytomegalovirus disease. Recent Pat Antiinfect Drug Discov 2: 53–72.
- Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W et al. (2003) Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 143: 16–25.
- Kimberlin DW, Jester PM, Sanchez PJ, Ahmed A, Arav-Boger R et al. (2015) Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 372: 933–943. 10.1056/NEJMoa1404599
- Jabs DA, Martin BK, Forman MS (2010) Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS. Ophthalmology 117: 128–132. 10.1016/j.ophtha.2009.06.016
- Chou SW (2001) Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 3 Suppl 2: 20–24.
- Krosky PM, Baek MC, Coen DM (2003) The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol 77: 905–914.
- Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ et al. (2003) In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother 47: 2186–2192.
- Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D et al. (2010) In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 54: 1290–1297. 10.1128/AAC.01596-09
- Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E et al. (2011) First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 11: 1079–1084. 10.1111/j.1600-6143.2011.03530.x
- Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R et al. (2008) Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 111: 5403–5410. 10.1182/blood-2007-11-121558
- Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M et al. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14: 762–766. 10.1038/nm1777
- Thoene JG, Lemons R, Boskovich S, Borysko K (1985) Inhibitors of protein synthesis also inhibit lysosomal proteolysis. Studies using cystinotic fibroblasts. J Clin Invest 75: 370–376.
- Entner N, Grollman AP (1973) Inhibition of protein synthesis: a mechanism of amebicide action of emetine and other structurally related compounds. J Protozool 20: 160–163.
- Madjar JJ, Nielsen-Smith K, Frahm M, Roufa DJ (1982) Emetine resistance in chinese hamster ovary cells is associated with an altered ribosomal protein S14 mRNA. Proc Natl Acad Sci U S A 79: 1003–1007.
- Zhou X, Hao Q, Liao J, Zhang Q, Lu H (2013) Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene 32: 388–396. 10.1038/onc.2012.63
- Riley MF, Lozano G (2012) The Many Faces of MDM2 Binding Partners. Genes Cancer 3: 226–239. 10.1177/1947601912455322
- Kulikov R, Winter M, Blattner C (2006) Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J Biol Chem 281: 28575–28583.
- Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1: 1001–1008.
- Worrall EG, Wawrzynow B, Worrall L, Walkinshaw M, Ball KL et al. (2009) Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif. J Chem Biol 2: 113–129. 10.1007/s12154-009-0019-5
- Zhang Z, Evers DL, McCarville JF, Dantonel JC, Huong SM et al. (2006) Evidence that the human cytomegalovirus IE2-86 protein binds mdm2 and facilitates mdm2 degradation. J Virol 80: 3833–3843. 80/8/3833 [pii];10.1128/JVI.80.8.3833-3843.2006
- Lurain NS, Chou S (2010) Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23: 689–712. 10.1128/CMR.00009-10
- Roy S, Arav-Boger R (2014) New cell-signaling pathways for controlling cytomegalovirus replication. Am J Transplant 14: 1249–1258. 10.1111/ajt.12725
- Kern ER, Collins DJ, Wan WB, Beadle JR, Hostetler KY et al. (2004) Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother 48: 3516–3522.
- Madjar JJ, Frahm M, McGill S, Roufa DJ (1983) Ribosomal protein S14 is altered by two-step emetine resistance mutations in Chinese hamster cells. Mol Cell Biol 3: 190–197.
- Browne EP, Wing B, Coleman D, Shenk T (2001) Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs. J Virol 75: 12319–12330.
- Hwang ES, Zhang Z, Cai H, Huang DY, Huong SM et al. (2009) Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. J Virol 83: 12388–12398. JVI.00304-09 [pii];10.1128/JVI.00304-09
- Casavant NC, Luo MH, Rosenke K, Winegardner T, Zurawska A et al. (2006) Potential role for p53 in the permissive life cycle of human cytomegalovirus. J Virol 80: 8390–8401. 80/17/8390 [pii];10.1128/JVI.00505-06
- Fortunato EA, Spector DH (1998) p53 and RPA are sequestered in viral replication centers in the nuclei of cells infected with human cytomegalovirus. J Virol 72: 2033–2039.
- Chen Z, Knutson E, Wang S, Martinez LA, Albrecht T (2007) Stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination. J Biol Chem 282: 29284–29295. M705349200 [pii];10.1074/jbc.M705349200
- Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299.
- Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387: 299–303.
- Diaz JJ, Roufa DJ (1992) Fine-structure map of the human ribosomal protein gene RPS14. Mol Cell Biol 12: 1680–1686.
- Boultwood J (2011) The role of haploinsufficiency of RPS14 and p53 activation in the molecular pathogenesis of the 5q- syndrome. Pediatr Rep 3 Suppl 2: e10 10.4081/pr.2011.s2.e10 pr.2011.s2.e10 [pii].
- Panettiere F, Coltman CA Jr. (1971) Experience with emetine hydrochloride (NSC 33669) as an antitumor agent. Cancer 27: 835–841.
- Mastrangelo MJ, Grage TB, Bellet RE, Weiss AJ (1973) A phase I study of emetine hydrochloride (NSC 33669) in solid tumors. Cancer 31: 1170–1175.
- Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659–661. fj.07-9574LSF [pii];10.1096/fj.07-9574LSF
- Regenthal R, Krueger M, Koeppel C, Preiss R (1999) Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput 15: 529–544.
- Knight R (1980) The chemotherapy of amoebiasis. J Antimicrob Chemother 6: 577–593.
- Muhammad I, Dunbar DC, Khan SI, Tekwani BL, Bedir E et al. (2003) Antiparasitic alkaloids from Psychotria klugii. J Nat Prod 66: 962–967.
- Carney RW, Wojtkunski J, Konopka EA, deStevens G (1966) The chemical, spectral, and biological properties of monomethine cyanine dyes containing 1,3-benzoxazine and quinazoline nuclei. J Med Chem 9: 758–762.
- Rosenkranz V, Wink M (2008) Alkaloids induce programmed cell death in bloodstream forms of trypanosomes (Trypanosoma b. brucei). Molecules 13: 2462–2473. 10.3390/molecules13102462
- Deng L, Dai P, Ciro A, Smee DF, Djaballah H et al. (2007) Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virol 81: 13392–13402.
- Chaves Valadao AL, Abreu CM, Dias JZ, Arantes P, Verli H et al. (2015) Natural Plant Alkaloid (Emetine) Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity. Molecules 20: 11474–11489. molecules200611474 [pii];10.3390/molecules200611474
- He R, Sandford G, Hayward GS, Burns WH, Posner GH et al. (2011) Recombinant Luciferase-Expressing Human Cytomegalovirus (CMV) for evaluation of CMV inhibitors. Virol J 8: 40 10.1186/1743-422X-8-40
- Lurain NS, Chou S (2010) Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23: 689–712. 10.1128/CMR.00009-10
- Summers BC, Margolis TP, Leib DA (2001) Herpes simplex virus type 1 corneal infection results in periocular disease by zosteriform spread. J Virol 75: 5069–5075.
- Fischer L, Laib SK, Jahn G, Hamprecht K, Gohring K (2013) Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation. Antiviral Res 100: 575–577. S0166-3542(13)00286-6 [pii];10.1016/j.antiviral.2013.09.026
- Cai H, Kapoor A, He R, Venkatadri R, Forman M et al. (2014) In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action. Antimicrob Agents Chemother 58: 986–994. AAC.01972-13 [pii];10.1128/AAC.01972-13
- Bliss C.I. (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26: 585–615.
- Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK et al. (2012) A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med 18: 446–451. 10.1038/nm.2649
- Liu J, Xu Y, Stoleru D, Salic A (2012) Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin. Proc Natl Acad Sci U S A 109: 413–418. 1111561108 [pii];10.1073/pnas.1111561108
- Iversen AC, Steinkjer B, Nilsen N, Bohnhorst J, Moen SH et al. (2009) A proviral role for CpG in cytomegalovirus infection. J Immunol 182: 5672–5681. 10.4049/jimmunol.0801268
- Vliegen I, Herngreen S, Grauls G, Bruggeman C, Stassen F (2003) Improved detection and quantification of mouse cytomegalovirus by real-time PCR. Virus Res 98: 17–25.
- Lal A, Haynes SR, Gorospe M (2005) Clean Western blot signals from immunoprecipitated samples. Mol Cell Probes 19: 385–388. S0890-8508(05)00044-7 [pii];10.1016/j.mcp.2005.06.007
- Pizzorno MC, O'Hare P, Sha L, LaFemina RL, Hayward GS (1988) trans-activation and autoregulation of gene expression by the immediate-early region 2 gene products of human cytomegalovirus. J Virol 62: 1167–1179.
- Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P et al. (2008) Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451: 335–339. nature06494 [pii];10.1038/nature06494
- Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J et al. (2013) TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A 110: 16127–16132. 1311055110 [pii];10.1073/pnas.1311055110
- Tiscornia G, Singer O, Ikawa M, Verma IM (2003) A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci U S A 100: 1844–1848.
- Kapoor A, Forman M, Arav-Boger R (2014) Activation of nucleotide oligomerization domain 2 (NOD2) by human cytomegalovirus initiates innate immune responses and restricts virus replication. PLoS One 9: e92704 10.1371/journal.pone.0092704 PONE-D-13-49464 [pii].
Source: PubMed